Recent data reveals that retatrutide, a innovative medication, could represent a major step in body loss . This drug combines the properties of a GLP-1 agonist and a GIP agonist , possibly offering a enhanced impact than current solutions. Study trials have revealed encouraging findings , including substantial reductions in size and improvements in